We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+40.24%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$356M
AUM Growth
+$164M
Cap. Flow
+$115M
Cap. Flow %
32.2%
Top 10 Hldgs %
50.6%
Holding
52
New
19
Increased
13
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$20.1M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$13.7M
3
RVNC
Revance Therapeutics, Inc.
RVNC
+$7.91M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$7.48M
5
ALT icon
Altimmune
ALT
+$6.42M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$5.7M
2
MRUS
Merus
MRUS
+$5.66M
3
FOLD
Amicus Therapeutics
FOLD
+$5.57M
4
ARVN icon
Arvinas
ARVN
+$4.63M
5
COGT icon
Cogent Biosciences
COGT
+$4.11M

Sector Composition

Rank Sector Weight
1 Healthcare 68.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
26
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.03M 1.41%
+200,000
New +$5.54M
SNDX icon
27
Syndax Pharmaceuticals
SNDX
$2.02B
$4.81M 1.35%
200,000
-25,000
-11% -$561K
HZNP
28
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.64M 1.3%
75,000
-25,000
-25% -$1.75M
ATXS
29
DELISTED
Astria Therapeutics
ATXS
$4.52M 1.27%
+500,000
New +$3.35M
KZR
30
DELISTED
Kezar Life Sciences
KZR
$4.52M 1.27%
52,500
+7,500
+17% +$729K
BPMC
31
DELISTED
Blueprint Medicines
BPMC
$4.28M 1.2%
+65,000
New +$4.17M
WHWK
32
Whitehawk Therapeutics
WHWK
$192M
$2.83M 0.79%
200,000
+50,000
+33% +$657K
ITCI
33
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.79M 0.78%
+60,000
New +$3.13M
JBIO
34
Jade Biosciences
JBIO
$1.27B
$2.49M 0.7%
+4,286
New +$2.86M
MLTX icon
35
MoonLake Immunotherapeutics
MLTX
$1.64B
$2.33M 0.65%
300,000
– –
RAPT
36
DELISTED
RAPT Therapeutics
RAPT
$2.17M 0.61%
11,250
-9,375
-45% -$1.77M
TCDA
37
DELISTED
Tricida, Inc. Common Stock
TCDA
$2.1M 0.59%
+200,000
New +$2.19M
TARS icon
38
Tarsus Pharmaceuticals
TARS
$2.61B
$2.05M 0.58%
120,000
– –
DSGN icon
39
Design Therapeutics
DSGN
$785M
$1.67M 0.47%
100,000
-175,000
-64% -$3.48M
MDGL icon
40
Madrigal Pharmaceuticals
MDGL
$12.8B
$1.63M 0.46%
+25,000
New +$1.74M
RYTM icon
41
Rhythm Pharmaceuticals
RYTM
$7.31B
$1.59M 0.45%
+65,000
New +$1.21M
ISEE
42
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.1M 0.31%
+61,300
New +$805K
BIIB icon
43
Biogen
BIIB
$30.4B
$1M 0.28%
+3,750
New +$796K
SYRE icon
44
Spyre Therapeutics
SYRE
$8.7B
$526K 0.15%
40,000
+3,000
+8% +$37.1K
ALNY icon
45
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-1,900
Closed -$277K
ARVN icon
46
Arvinas
ARVN
$517M
– –
-110,000
Closed -$4.63M
CLDX icon
47
CALL
Celldex Therapeutics
CLDX
$2.77B
– –
-400,000
Closed -$10.8M
MRUS
48
DELISTED
Merus
MRUS
– –
-250,000
Closed -$5.66M
XBI icon
49
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-50,000
Closed -$3.71M
SGEN
50
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-35,000
Closed -$5.7M
1
2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Ghost Tree Capital held 52 positions worth $356M, up 86% from $192M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Ghost Tree Capital deployed $115M of net new capital in Q3 2022, opening 19 new positions and adding to 13 existing holdings. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 725,000 shares worth $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 76% a quarter earlier.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $5.57M trimmed.

  • Ghost Tree Capital's largest Q3 2022 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 725,000 shares worth $18.2M.
  • Ghost Tree Capital added most to CTI BioPharma Corp. (DE) Common Stock in Q3 2022, an estimated $7.48M increase.
  • Ghost Tree Capital's biggest Q3 2022 reduction was Amicus Therapeutics, cutting an estimated $5.57M.
  • Ghost Tree Capital fully exited Seagen Inc. Common Stock in Q3 2022, selling an estimated $5.7M.
  • Ghost Tree Capital's ten largest holdings make up 51% of its $356M portfolio in Q3 2022.
  • Ghost Tree Capital opened 19 new positions and closed 8 in Q3 2022.
  • Ghost Tree Capital's portfolio value rose 86% quarter-over-quarter to $356M.

Based on Ghost Tree Capital's 13F filing for Q3 2022, filed 14 Nov 2022.